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INDICATIONS FOR ECHOCARDIOGRAPHY 
IN CORONARY RISK STRATIFICATION
BEFORE NON-CARDIAC SURGERY
Cardiac complications are responsible for the main adverse
events following major surgery and detecting patients at high
risk of a per- or post-operative coronary event would seem
extremely useful. It is important before the procedure to
investigate for these as thoroughly as possible and thereafter
to monitor the patient at close intervals per and post-operati-
vely. Coronary risk was initially assessed in patients who had
undergone vascular surgery [1-4] because of the high preva-
lence of coronary artery lesions in this population. There are
many risk factors, involving clinical, electrocardiographical
and historical findings and also the type of surgical procedure
planned. This makes stratification difficult and requires a suc-
cessive stepwise assessment to be used.
Clinical risk markers have been established from large
series and are proposed in the North American recommenda-
tions (table 1) [5]. In order to facilitate clinical risk assess-
ment, some authors have proposed a simplified score which is
currently used by most teams (table 2). Clinical markers are
not however sufficient as the surgical procedure also influen-
ces the incidence of cardiovascular complications (table 1).
The first, clinical and electrocardiographical, stage is used to
detect patients at lower risk (patients with one or more minor
risk factors but no intermediate or major risk factors). If func-
tional capacity is good in this group (clinical evaluation and if
uncertain, exercise test), surgery can be proposed with no
other investigations (table 3). If the clinical assessment
detects factors suggesting high clinical risk the surgical proce-
dure should be postponed and a full cardiological assessment,
possibly combined with coronary angiography, should be
obtained. Patients at intermediary risk from the clinical fin-
dings in practice represent a large proportion (69% of patients
in a recent general surgical series) [6]. The management of
this group is still being debated and there is no single defini-
tion of the group. One definition often used is the presence or
1 or 2 intermediary clinical risk factors. Functional capacity
should be assessed first line with an exercise test which is use-
ful prognostically but its feasibility is often limited in an
elderly population with poor functional capacity [7, 8]. If
satisfactory and if the procedure is not high risk, surgery may
then be considered (possibly under beta blocker cover, see
below). If functional capacity is poor or unassessable or if the
surgery is intermediary or at high risk, a functional test is
appropriate (table 3). This is the situation in which stress
echocardiography (most often with dobutamine) has a role as
it is easy to perform and very widely studied in this type of
population.
Published studies on dobutamine echocardiography mostly
involve vascular surgery with an assessment of immediate
pre-operative and late prognosis. All of these indicate that the
investigation has excellent negative predictive value (97 to
100%) [1-4]. Development of a wall motion abnormality during
the test is however an independent predictive factor for per-
operative ischaemic events. The positive predictive value of
the investigation for serious events (death or infarction) is
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however relatively low (38% in the larger series) [9]. The heart
rate at which ischaemia develops (ischaemic threshold <70% of
MPHR) is an independent predictive factor for post-operative
events and can increase the positive predictive value of the
investigation to 53%. All patients who had a serious event (MI
or death) were in this group [9].
The prognostic value of stress echocardiography distant to
vascular surgery was confirmed by the same authors (10] in a
series of 316 patients followed up for 19±11 months. Two fac-
tors emerged as predictive of late cardiac events: a past his-
tory of MI (RR=3.8) and the extent of ischaemia in the pre-ope-
rative dobutamine echocardiogram (RR=6.5 when the number
of ischaemic segments was 3 or more).
These findings on the prognostic value of pre-operative
stress echocardiography have been confirmed before major
non-vascular surgery [6]. A dobutamine stress echocardiogra-
phy was performed in 530 patients unable to undergo an exer-
cise test prior to major non-vascular surgery in order to stra-
tify per-operative cardiac risk. This study confirmed that the
investigation had an excellent negative predictive value, all of
the cardiac events occurring in patients who had myocardial
ischaemia (NPV=100%). The positive predictive value of the
test was low (15%), although increased to 43% for a heart rate
ischaemic threshold of below 60% of MPHR, confirming the
results of Poldermans and co-workers [9] before vascular sur-
gery. There is at present no published work on the prognostic
value of stress echocardiography distant to major non-vascular
surgery.
Stress echocardiography and myocardial scintigraphy
have a similar diagnostic performance in screening for coro-
nary artery disease [11]. Many studies have been conducted in
pre-operative coronary risk assessment, mostly in candidates
for vascular surgery [12-14].
Meta-analyses of these studies have concluded either that
the two techniques performed similarly [15,16] or, more
recently, in a meta-analysis published by Kertaï et al. on 8119
patients [17] that stress echocardiography was statistically
significantly superior to myocardial scintigraphy, in particular
with a better positive predictive value for the development of
per-operative cardiac complications. Stress echocardiography
is therefore useful to assess and stratify pre-operative coro-
nary risk.
The role of stress echocardiography should be incorporated
into the perioperative therapeutic strategy for these
patients. 
Beta blockers are the cornerstone of treatment, producing
a significant reduction in the incidence of cardiac events both
per-operatively and late after the surgery. The first study,
published in 1999 [18], was a randomised prospective study of
the effect of a beta blocker (bisoprolol) versus placebo on
peroperative morbidity and mortality in major vascular sur-
gery in high risk patients with ischaemia in a pre-operative
stress echo. One hundred and seventy-three of 846 patients
with one or more risk factors had ischaemia in the stress echo.
Fifty-nine ultimately received bisoprolol and 53 the placebo
Table 1 Pre-operative clinical assessment.
1/ Clinical risk factors
— Major (high clinical risk)
• Acute or recent myocardial infarction (with residual 
ischaemia), unstable or severe angina
• Decompensated heart failure 
• Severe arrhythmias: High degree AVB, symptomatic 
ventricular arrhythmia, supra-ventricular arrhythmia 
with rapid heart rate 
• Severe heart valve disease.
— Intermediate (intermediate clinical risk)
• Stable angina
• Past history of myocardial infarction (clinical history 
or ECG Q wave).
• Stable heart failure
• Diabetes (particularly insulin-dependent)
• Renal insufficiency.
— Minor (low clinical risk)
• High age (over 70 years old)
• Abnormal ECG (LVH, LBBB, ST abnormalities).
• Non-sinus rhythm (generally AF)
• Reduced functional capacity 
• Past history of cerebrovascular accident 
• Poorly controlled hypertension.
2/ Type of surgery
— High cardiac risk (>5%)
• Surgical emergencies, particularly in the elderly 
• Aortic or major vascular surgery 
• Peripheral vascular surgery 
• Long procedures with bleeding risk
— Intermediate risk (1 to 5%)
• Carotid endarteriectomy 
• Head and neck surgery
• Orthopaedic surgery 
• Thoracic or intraperitoneal surgery
• Prostate surgery 
— Low risk (<1%)
• Endoscopies
• Superficial surgery
• Cataract surgery 
• Breast surgery. 
Table 2 Simplified clinical risk score before non-cardiac
surgery (from ref. 21).
Clinical risk markers:
Age ≥70 years
Current angina
Past history of myocardial infarction
Heart failure 
Treatment for ventricular arrhythmia 
Past history of ischaemic cerebral event
Diabetes
Renal insufficiency
Risk assessment:
Low clinical risk: no marker 
Intermediate clinical risk: 1 or 2 markers 
High clinical risk: 3 or more markers
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Table 3 Risk stratification algorithm before non-urgent, non-cardiac surgery.
Stage 1 Clinical risk assessment
Stage 2 Functional capacity (clinical evaluation +/– exercise test)
Stage 3 Level of risk of the intended surgical procedure
Good Poor
Low clinical risk (stage1) Intermediate clinical risk (stage 1)
(stage 1)
Low clinical risk (stage 1)
Low Intermediate High
Consider coronary angiography, or surgery on beta blockers.  
Low Intermediate
2 options
High
Surgery Functional test 
Negative test 
or limited ischaemia 
Early and/or  
extensive ischaemia
Postpone procedure + full 
cardiological assessment
Surgery  Intermediate 
clinical risk 
+  beta blockers
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(61 patients were excluded as they were already taking a beta
blocker or had early severe ischaemia). Two patients in the
beta blocker group (3.4%) and 18 patients in the placebo group
(34%, p<0.001) developed the combined criterion of either
cardiac death or non-fatal MI. The risk of peri-operative mor-
bidity-mortality was therefore reduced by a factor of 10 by
taking beta blocker treatment. The same patient population
was followed up for an average of 2 years after surgery and
the benefit of bisoprolol treatment was found to be maintai-
ned long term (12% cardiac events with bisoprolol compared
to 32% on placebo, p=0.025) [19]. The benefits of beta blocker
treatment (pre-operative IV Atenolol) had already been shown
[20] in patients with coronary artery disease or at risk of coro-
nary artery disease without documented ischaemia who were
undergoing non-cardiac surgery (vascular in 40% of cases).
The benefit in this situation was a significant reduction in total
mortality due to a reduction in cardiac deaths in the beta
blocker group which was seen within 6-8 months after surgery
and was maintained for 2 years. Work derived from the biso-
prolol study showed the limited utility of dobutamine echocar-
diography in patients who had only one or two clinical risk fac-
tors (table 2) and pre-operative beta blocker treatment [21].
The serious event rate in this group was low (0.8%) and the
test did not provide significant prognostic information. On the
other hand, patients with widespread ischaemia had a high
event rate (36%). In order to provide more information about
these findings the DECREASE II trial published by the same
group in 2006 was a randomised prospective trial of the role of
dobutamine echocardiography compared to systematic beta
blocker treatment in 770 patients with 1 or 2 clinical risk fac-
tors, awaiting vascular surgery [22]. The patients were rando-
mised between dobutamine echocardiography and systematic
beta blocker. Revascularisation was considered in patients in
the stress echo group who had widespread ischaemia (invol-
ving at least 5 segments). Beta blocker therapy was started if
limited ischaemia was found, in order to avoid the HR excee-
ding the ischaemic threshold. Finally, patients with a negative
test underwent surgery with no additional treatment. This
study showed that no strategy was superior to any other for
death or myocardial infarction (1.8 versus 2.3%). The authors
concluded that systematic beta blocker therapy could be used
to substitute for a functional investigation strategy in this
patient group, particularly as in their study, performing stress
echocardiography delayed surgery by approximately 3 weeks.
Several comments may be made about this conclusion. Firstly
the investigation delay varies greatly between centres: this
must be kept short in order not to expose the patient to exces-
sive risk. It is also important to consider the beta blocker
treatment protocol which began orally before surgery but
which notably was then switched to intravenous, with hourly
monitoring of the HR in order that it did not exceed 60 to
65/min. This was undoubtedly a crucial factor in obtaining the
observed efficacy although requires very close interval moni-
toring. Finally, it is important to remember that the finding of
ischaemia on stress echocardiography reduces the patient’s
medium term prognosis, independently of surgery. This must
be considered in the debate.
The second treatment which appears to be effective in
reducing the coronary risk is statins. An initial retrospective
study [23], in 2816 patients undergoing vascular surgery
showed statins to impact in hospital mortality. Fewer people
who were taking a statin died from a cardiovascular cause
than controls (8% versus 25%, p<0.001), with a relative risk of
operative mortality of 0.22 in patients taking the statin com-
pared to those who were not. The same authors demonstrated
the statins to be safe, with no increase in the risk of myopathy
[24]. Their potential utility was confirmed by another group
[25] in a retrospective study in patients undergoing non-car-
diac surgery. This study showed a significant reduction in total
hospital mortality in the patient group receiving a statin,
which was greater in patients at high cardiac risk. Prospective,
randomised studies are now required to validate the utility of
statin treatment in reducing perioperative coronary risk.
Coronary revascularisation prior to surgery has not yet
been shown to be useful in patients with coronary artery
disease. In the CARP study [26], 510 patients at increased car-
diovascular risk (clinical risk factors and/or ischaemia
demonstrated on scintigraphy) with documented coronary
artery disease were randomised into 2 groups: one group
revascularised before surgery and one group which was not
revascularised. The patients were awaiting vascular surgery
(33% for abdominal aortic aneurysm, 67% for lower limb arte-
rial disease). Coronary revascularisation was performed on a
non-randomised basis by bypass in 41% of cases and by angio-
Table 4 Echocardiographical parameters to be recorded during stress echo (exercise or dobutamine).
Parameter Threshold/quantification Technical comment Indication Prognostic value
Wall motion 
abnormality
— New abnormality 
— Or deterioration vs. rest
— Affecting at least 1 segment
Interpretation difficulty: 
inferobasal segment 
or postero-basal IVS
systematic — Excellent NPV
— Low PPV
(for vasc. or non-vascular surgery)
Extent of 
ischaemia
Number of ischaemic segments Difficulty when resting 
WM abnormality is
present
systematic — Probably reduced protective 
role of beta blockers 
— Number >3 predictive of 
increased post-operative risk (vasc)
Ischaemic 
threshold
— HR at which ischaemia 
develops 
— <60% MPHR 
(non-vasc. surgery)
— <70% MPHR (vasc. surgery)
Stop beta blocker 48h
before investigation
systematic — Per-operative prognostic value 
— No post-operative prognostic 
value 
NPV: negative predictive value, PPV: positive predictive value, HR: heart rate, MPHR: maximum predicted heart rate, 
IVS: interventricular septum, vasc: vascular.
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plasty in 59% of cases. Clinical features, beta blocker and sta-
tin use were identical in the two groups. The mortality rate
after a mean follow-up period of 2.7 years was 22% in the
revascularised group and 23% in the non-revascularised group
(p=0.92). The MI rate diagnosed from a rise in troponin in the
30 days following surgery was 12% in the revascularised group
and 14% in the non-revascularised group (p=0.37). This study
therefore appears to indicate that coronary revascularisation
before major vascular surgery is not beneficial in the short or
long term in stable coronary artery disease patients. This
result, however, should be interpreted with caution as this
was a study on an average population size with probable
recruitment bias: only 62% of the patients had had scintigra-
phy and only 74% were actually at increased cardiovascular
risk. Back and co-workers [27] had already shown that recent
coronary revascularisation (<5 years) by bypass or angioplasty
had no effect on the long term survival (5 years) in patients at
high cardiovascular risk awaiting vascular surgery. This crite-
rion however was only a secondary end point for the study,
limiting its value.
Conclusion: Stress echocardiography is a useful examina-
tion to stratify coronary risk in patients with clinical risk fac-
tors before surgery and has immediate and late prognostic
implications. It must include both the positive diagnosis of
myocardial ischaemia (development of WM abnormality) and
also its extent and the HR threshold at which the ischaemia
occurs (table 4). Beta blocker (and possibly statin) treatment
is useful in reducing morbidity and mortality before vascular
surgery. This must be widely used and can avoid the need for
functional tests when the procedure is to be performed shortly
and the patient is not at high risk. Coronary revascularisation
before surgery has not however been proven to be effective
and therefore should be considered on an individual case
basis.
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